Interview with Ralf Vayntrub, Founder & President, Invar
The following is joint interview of Mr. Vayntrub and Regina Karymova, General Manager of Invar Mr. Vayntrub, you founded Invar in 1991, and began to capitalize on foreign investment in…
Address: 2 Ploshchad Zhuravleva, bld.2, 107023 Moscow,Russia
Tel: +7 (495) 962-16-62
Web: http://www.invarpharma.com/
INVAR is the Russian, privately-owned, national pharmaceutical & biotechnology company forming a product portfolio on the basis of
long-term exclusive in-licensing or distribution agreements on marketing and sales for the Russian market with owners of innovative medicines.
Number of employees – 104
Activity areas: Gynecology and Obstetrics, Dermatology, Otolaryngology, Pediatrics
Areas of interest: Innovative original pharmaceuticals, preferably in the spheres of dermatology, gynecology, otorhinolaryngology (ENT) and pediatrics
Company geography: Representation in 15 key regions of the Russia
Our dedicated team performs all key business processes:
• Regulatory & Clinical Affairs
• Marketing
• Sales Forces Organization
• Logistics & Supply Chain
• Commercial Operations
Products: Fluomizin, Gynoflor E (Medinova, Switzerland), Sinuforte (Hartington S.L., Spain), Epigen (Cheminova S.A., Spain), Skin Cap (Cheminova S.A., Spain)
Services: Registration, promotion and distribution of innovative pharmaceutical products within the territory of the Russia
The following is joint interview of Mr. Vayntrub and Regina Karymova, General Manager of Invar Mr. Vayntrub, you founded Invar in 1991, and began to capitalize on foreign investment in…
Although Russian authorities received heavy criticism for approving the Sputnik V vaccine prior to the completion of Phase III clinical trials, the jab is increasingly being seen as a viable…
Russia has announced that a domestically developed COVID-19 vaccine has been approved by its health authorities, the first such approval globally. However, with large-scale Phase III trials having not yet…
Below is a selection of top stories in Russian pharma from recent months, ranging from proposed changes in legislation, labelling system updates, priorities set forth by the country’s manufacturing association…
Russia is facing a drug shortage crisis which is having a particular impact on patients with life-threatening conditions. A combination of geopolitical and bureaucratic issues are restricting the flow of…
In the latest twist in the ongoing story of Russian interference in the US presidential elections of 2016, it has emerged that Russian internet trolls and automated bots spread misinformation…
In the United States, Johnson & Johnson has an image of being very close to people. Americans grow up with this company — from baby shampoo, to Tylenol when they…
You took over this organization just three months ago, having previously headed businesses in industries as diverse as retail, food, and automobiles. What drew you to Alliance Healthcare Russia? Do…
The ARPM was founded in 2002, and you were its director from 2002-2004, before leaving for a post at the Roszdravnadzor. You’ve since rejoined as director since 2007. The organization…
When Focus Reports prepared a report on the French pharmaceutical industry in 2009/10, we found that the head of the main multinational pharmaceutical association had taken a career path quite…
The U.S. and Russia have a long history of trade, and you have personally been with the American Chamber of Commerce in Russia since 2001. Can you give a brief…
The primary objectives of this association are to promote Russia as a clinical trial destination, optimize the regulatory and legislative environment, and promote the interests of ACTO members. Can you…
You have said that AstraZeneca intends to be “in Russia for Russia” and the company has recently announced a large-scale investment in this country, financing a $150Mn domestic facility in…
See our Cookie Privacy Policy Here